Drug reference

Cetuximab

Monoclonal Antibody · Antineoplastic Agent

Monoclonal AntibodyAntineoplastic AgentATC null

CDSCO approvedSchedule H

EXCRETION

—

not curated

INTERACTIONS

2 major

SEVERE in our sources

PREGNANCY

Avoid—toxicity in animal studies.

FDA category + note

Top interactions

Aminolevulinic AcidSevereDatabaseDDInter
ThalidomideSevereDatabaseDDInter

Mechanism

Cetuximab is a monoclonal antibody that specifically targets the extracellular ligand-binding domain of the Epidermal Growth Factor Receptor (EGFR). By binding to EGFR, it competitively blocks the attachment of natural ligands, thereby inhibiting downstream signaling pathways crucial for cell growth, proliferation, and survival. This action leads to reduced tumor growth in EGFR-expressing cancers.

Indications

Treatment of wild-type RAS metastatic colorectal cancer in patients with tumours expressing epidermal growth factor receptor, as combination therapy, or as monotherapy if oxaliplatin- and irinotecan-based therapy has failed or if irinotecan is not toleratedTreatment of locally advanced squamous cell cancer of the head and neckcolorectal cancer (KRAS wild type)metastatic colorectal cancer with wild-type KRAS in combination with chemotherapyhead and neck squamous cell carcinoma (HNSCC) in combination with radiation or cisplatinmonotherapy for patients with metastatic or recurrent HNSCC whose disease progresses on platinum-based chemotherapyAdvanced/metastatic squamous carcinoma of head and neckEGF receptor positive metastatic colorectal cancer

Dosing

Adult: with paclitaxel for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vascular endothelial growth factor (VEGF) inhibitors or VEGF receptor-targeted agents.…